Shiro Ikegawa

Shiro Ikegawa

Auto-generated profile, based on publicly available information

Shiro Ikegawa

Laboratory of Bone and Joint Diseases, Center for Genomic Medicine, RIKEN, 4‐6‐1 Sirokanedai, Minato‐ku, Tokyo 108‐8639, Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
KIKazuyoshi Ishigaki
Kazuyoshi Ishigaki
MAMasato Akiyama
Masato Akiyama
MKMasahiro Kanai
Masahiro Kanai
ATAtsushi Takahashi
Atsushi Takahashi
EKEiryo Kawakami
Eiryo Kawakami
YKYoichiro Kamatani
Yoichiro Kamatani

1 September 2021 in Cell
Verified
Journal Article
Open access
CBCindy G. Boer
Cindy G. Boer
KHKonstantinos Hatzikotoulas
Konstantinos Hatzikotoulas
LSLorraine Southam
Lorraine Southam
LSLilja Stefánsdóttir
Lilja Stefánsdóttir
YZYanfei Zhang
Yanfei Zhang
EZEleftheria Zeggini
Eleftheria Zeggini
Osteoarthritis affects over 300 million people worldwide. Here, we conduct a genome-wide association study meta-analysis across 826,690 individuals (177,517 with osteoarthritis) and identify 100 independently associated risk variants across 11 osteoarthritis phenotypes, 52 of which have not been associated with the disease before. We report thumb and spine osteoarthritis risk variants and identify differences in genetic effects between weight-bearing and non-weight-bearing joints. We identify sex-specific and early age-at-onset osteoarthritis risk loci. We integrate functional genomics data from primary patient tissues (including articular cartilage, subchondral bone, and osteophytic cartilage) and identify high-confidence effector genes. We provide evidence for genetic correlation with phenotypes related to pain, the main disease symptom, and identify likely causal genes linked to neuronal processes. Our results provide insights into key molecular players in disease processes and highlight attractive drug targets to accelerate translation.

4 November 2004 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
TIToshiyuki Ikeda
Toshiyuki Ikeda
SKSatoru Kamekura
Satoru Kamekura
AMAkihiko Mabuchi
Akihiko Mabuchi
IKIkuyo Kou
Ikuyo Kou
SSShoji Seki
Shoji Seki
UCUng‐Il Chung
Ung‐Il Chung
Objective: To regenerate permanent cartilage, it is crucial to know not only the necessary conditions for chondrogenesis, but also the sufficient conditions. The objective of this study was to determine the signal sufficient for chondrogenesis.Methods: Embryonic stem cells that had been engineered to fluoresce upon chondrocyte differentiation were treated with combinations of factors necessary for chondrogenesis, and chondrocyte differentiation was detected as fluorescence. We screened for the combination that could induce fluorescence within 3 days. Then, primary mesenchymal stem cells, nonchondrogenic immortalized cell lines, and primary dermal fibroblasts were treated with the combination, and the induction of chondrocyte differentiation was assessed by detecting the expression of the cartilage marker genes and the accumulation of proteoglycan‐rich matrix. The effects of monolayer, spheroid, and 3‐dimensional culture systems on induction by combinations of transcription factors were compared. The effects of the combination on hypertrophic and osteoblastic differentiation were evaluated by detecting the expression of the characteristic marker genes.Results: No single factor induced fluorescence. Among various combinations examined, only the SOX5, SOX6, and SOX9 combination (the SOX trio) induced fluorescence within 3 days. The SOX trio successfully induced chondrocyte differentiation in all cell types tested, including nonchondrogenic types, and the induction occurred regardless of the culture system used. Contrary to the conventional chondrogenic techniques, the SOX trio suppressed hypertrophic and osteogenic differentiation at the same time.Conclusion: These data strongly suggest that the SOX trio provides signals sufficient for the induction of permanent cartilage.

1 April 2020 in Nature
Verified
Journal Article
Closed access
PDF file
MMMitsuhiro Matsuda
Mitsuhiro Matsuda
YYYoshihiro Yamanaka
Yoshihiro Yamanaka
MUMaya Uemura
Maya Uemura
MOMitsujiro Osawa
Mitsujiro Osawa
MSMegumu Saito
Megumu Saito
CACantas Alev
Cantas Alev

27 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MAMasato Akiyama
Masato Akiyama
KIKazuyoshi Ishigaki
Kazuyoshi Ishigaki
SSSaori Sakaue
Saori Sakaue
YMYukihide Momozawa
Yukihide Momozawa
MHMomoko Horikoshi
Momoko Horikoshi
YKYoichiro Kamatani
Yoichiro Kamatani
Human height is a representative phenotype to elucidate genetic architecture. However, the majority of large studies have been performed in European population. To investigate the rare and low-frequency variants associated with height, we construct a reference panel (N = 3,541) for genotype imputation by integrating the whole-genome sequence data from 1,037 Japanese with that of the 1000 Genomes Project, and perform a genome-wide association study in 191,787 Japanese. We report 573 height-associated variants, including 22 rare and 42 low-frequency variants. These 64 variants explain 1.7% of the phenotypic variance. Furthermore, a gene-based analysis identifies two genes with multiple height-increasing rare and low-frequency nonsynonymous variants (SLC27A3 and CYP26B1; PSKAT-O < 2.5 × 10−6). Our analysis shows a general tendency of the effect sizes of rare variants towards increasing height, which is contrary to findings among Europeans, suggesting that height-associated rare variants are under different selection pressure in Japanese and European populations.

1 July 2000 in Cytogenetic and Genome Research
Verified
Journal Article
Closed access
PDF file
SIS. Ikegawa
S. Ikegawa
MSM. Sano
M. Sano
YKY. Koshizuka
Y. Koshizuka
YNY. Nakamura
Y. Nakamura
PRG4 (proteoglycan 4) has been identified as megakaryocyte stimulating factor and articular superficial zone protein. PRG4 has characteristic motifs including somatomedin B and hemopexin domains, a chondroitin sulfate-attachment site and mucin-like repeats. During a screen of genes implicated in ectopic ossification, we found a novel mouse gene highly homologous to human and bovine PRG4 genes. Here, we report isolation, characterization and mapping of the gene, Prg4 together with characterization of its human orthologue. Prg4 cDNA was 3,320 bp long, encoding a 1,054 amino-acid protein. Human and mouse PRG4 genes each consisting of 12 exons spanned 18 and 16 kb, respectively. Characteristic motifs were conserved across species; however, the mucin-like repeat regions were highly diverse in length between species with a tendency that larger animals had longer repeats. Expression of human and mouse PRG4 genes was similar and found not only in cartilage, but also in liver, heart, lung, and bone. Expression of the mouse gene increased with progression of ectopic ossification. Multiple tissue-specific splicing variants lacking some of the motifs were found in both human and mouse. Although a specific role in the articular joint has previously been reported, the presence of multi-functional motifs as well as unique expression and alternative splicing patterns suggest that PRG4 functions in several distinctive biological process including regulation of ossification.